TGF-beta receptor 1 kinase inhibitor (Boehringer Ingelheim)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTGF-beta receptor 1 kinase inhibitor (Boehringer Ingelheim)
Drug Alias NameALK-5 inhibitors (Boehringer Ingelheim)BIBF-0775
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTransforming growth factor beta receptor 1 inhibitors
TargetsTransforming growth factor beta receptor 1
Therapy Area/IndicationsPulmonary FibrosisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBoehringer Ingelheim International Gmbh
Active IndicationsN/A
Inactive IndicationsPulmonary FibrosisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A